Danaparoid
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Danaparoid: From Anticoagulation (HIT) to Glanzmann Thrombasthenia
One-Sentence Summary
Danaparoid is a heparinoid anticoagulant conventionally used to manage heparin-induced thrombocytopenia (HIT), where its mechanism is Factor Xa/IIa inhibition to reduce clot formation. The TxGNN model’s top prediction is Glanzmann Thrombasthenia, a congenital bleeding disorder — but this candidate is currently supported by 0 clinical trials and 0 publications, and the drug’s mechanism runs in the opposite direction to what the disease requires.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Heparin-induced thrombocytopenia (HIT) / anticoagulation, based on known clinical use — no MHRA-approved indication text is present in this dataset |
| Predicted New Indication | Glanzmann Thrombasthenia |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available from official sources for this candidate (marked as a data gap). However, from known pharmacology, Danaparoid is a heparinoid that acts primarily via antithrombin-mediated inhibition of Factor Xa (with minor Factor IIa activity), reducing the blood’s clotting capacity. It is clinically used for anticoagulation in patients with HIT.
Glanzmann Thrombasthenia is a congenital bleeding disorder caused by a defect in the platelet GPIIb/IIIa receptor, which impairs platelet aggregation. Patients with this condition already have reduced, not excessive, clotting capacity. Administering an anticoagulant such as Danaparoid would not correct the underlying receptor defect and could plausibly worsen bleeding risk rather than treat the disease.
This mismatch suggests the high TxGNN score most likely reflects a directional artefact in the knowledge graph — the model appears to be picking up “drug–platelet pathway” node proximity without distinguishing between a pro-coagulant deficiency (which needs pro-haemostatic treatment) and an anticoagulant therapy (which treats excessive clotting). The same pattern applies to the other five predicted indications in this evidence pack (primary platelet release disorder, pseudo-von Willebrand disease, collagen receptor defect bleeding diathesis, constitutional thrombocytopenia, and Scott syndrome) — all are congenital bleeding/platelet disorders where an anticoagulant is mechanistically contraindicated rather than therapeutic.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Danaparoid is currently not marketed under this evidence pack’s regulatory dataset, and no marketing authorisation record is available (0 licences on file). No product/dosage form information can be provided.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: this evidence pack flags TFDA-equivalent labelled warnings/contraindications as a Blocking data gap (DG001) and mechanism-of-action detail as a High severity data gap (DG002) — neither is available for independent verification at this time.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence level is L5 (model prediction only — no clinical trials or literature identified for any of the 6 candidate indications), and the drug’s known mechanism (anticoagulation) is directionally opposed to the therapeutic need in Glanzmann Thrombasthenia and the other candidate diseases (all bleeding/platelet-function disorders). There is a plausible risk of harm rather than benefit if pursued clinically.
To proceed, the following is needed:
- Resolution of the Blocking data gap (DG001): official labelled warnings/contraindications for Danaparoid
- Resolution of the High-severity data gap (DG002): confirmed mechanism of action detail, to formally assess mechanistic plausibility
- A mechanistic review of why TxGNN is scoring anticoagulants highly against congenital bleeding disorders, to determine whether this reflects a systematic direction-of-effect issue in the knowledge graph
- Independent pharmacological or expert clinical review before this candidate is considered for any further evaluation stage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.